Tafamidis meglumine | FoldRx Pharma | ||
20 mg; Capsules |
Less Than $1000 mn
|
||
Less Than 5
|
Less Than 5
|
||
Less Than 5
|
None | ||
None | None | ||
VYNDAQEL is transthyretin stabilizers indicated for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. | |||
Yes
|
Vyndaqel | Patent 1 | Patent 2 | Patent 3 | Patent 4 |
---|---|---|---|---|
********* | **** ** *** **, **** | **** ** *** **, **** | *** ********* | *** ********* |
Company | FTF Status / 180 days exclusivity | 30-Months stay | Current Litigation Status | Current Approval Status | Likelihood of launch |
---|---|---|---|---|---|
********* | *** / ********* | *** **, **** | ******* | **** | ** *** **, **** |